Glutathione-dependent system in the blood of gastric cancer patients with various tumor histotypes and prevalence of the disease

Purpose of the study. Exploring the erythrocyte glutathione system functioning in patients with gastric cancer in a comparative aspect, depending on tumor histotype and disease prevalence.

Patients and methods. The study included 89 patients with gastric cancer, divided into 6 groups depending on the histotype of the tumor. Separately, the results of the study were analyzed in patients with T4 status according to TNM and in patients at stage 4. The content of reduced glutathione and the activity of glutathione-dependent enzymes in the erythrocytes of the patients' blood were studied by conventional spectrophotometric methods. Statistical processing of the results was carried out using the Statistika 6.0 software package according to the Student's t-test and the nonparametric Wilcoxon-Mann-Whitney test for two independent samples.

Results. An increase in the content of glutathione was revealed in patients with gastric cancer compared with the group without oncopathology. The maximum increase was observed in patients with low-grade adenocarcinoma - by 42.5 %, while in signet ring cell carcinoma (SRCC) there was only a tendency to increase by 17.8 %. Glutathione reductase activity was decreased in adenocarcinoma by 23.4-26.2 % and did not change in SRCC. The activity of the antioxidant enzymes glutathione peroxidase and glutathione transferase was increased in all groups, and especially in SRCC - by 76 % and 23-29 %, respectively. In patients with the T4 status and at stage IV of the process, a lower activity of the studied glutathione-dependent enzymes was revealed in comparison with all other groups of patients.

Conclusions. The data obtained indicate a greater functional potential of the glutathione system in SRCC. A significant increase in glutathione transferase activity at a sufficiently high level of reduced glutathione can contribute to the development of treatment resistance in SRCC patients.

1. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1459-1544. https://doi.org/10.1016/S0140-6736(16)31012-1

2. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Beffio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356-387. https://doi.org/10.1016/j.ejca.2018.07.005

3. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239-248. https://doi.org/10.2147/CMAR.S149619

4. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-1953. https://doi.org/10.1002/ijc.31937

5. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Ed. by Kaprina AD, Starinsky VV, Petrova GV. M., 2019. Available at: https://oncology-association.ru/wp-content/uploads/2020/09/2018.pdf, Accessed: 04.09.2021. (In Russ.).

6. Kit OI, Samoylenko NS, Franzyants EM, Soldatkina NV, Sagakyants AB, Kharagezov DA, et al. Stomach cancer: modern directions of fundamental research. Modern problems of science and education. 2019;(4):136. Available at: https://s.science-education.ru/pdf/2019/4/28956.pdf, Accessed: 04.09.2021. (In Russ.).

7. Katelnitskaya OV, Kit OI, Katelnitsky II, Duritsky MN, Guskova NK, Gabrichidze PN, et al. Assessment of the efficacy of a peroral anticoagulant after surgical resection of gastric cancer. Cardiometry. 2018;(13):54-57. https://doi.org/10.12710/cardiometry.2018.13.5457

8. Kit OI, Vodolazhsky DI, Tatimov MZ, Vasilchenko NG, Pushkin AA, Kutsyn KA. and others. CNV genes as a biomarker and therapeutic target in gastric cancer. News of higher educational institutions. The North Caucasus region. Natural sciences. 2017;4-2(196-2):58-67. (In Russ.). https://doi.org/10.23683/0321-3005-2017-4-2-58-67

9. Merabishvili VM. Dynamics of observed and relative survival of patients with gastric cancer (population study). Questions of oncology. 2013;59(6):701-707. (In Russ.). https://doi.org/10.37469/0507-3758-2013-59-6-701-707

10. Coburn N, Cosby R, Klein L, Knight G, Malthaner R, Mamazza J, et al. Staging and surgical approaches in gastric cancer: A systematic review. Cancer Treat Rev. 2018 Feb;63:104-115. https://doi.org/10.1016/j.ctrv.2017.12.006

11. Merabishvili VM. Medium-term prognosis of cancer mortality among the population of Russia. Siberian Journal of Oncology. 2019;18(4):5-12. (In Russ.). https://doi.org/10.21294/1814-4861-2019-18-4-5-12

12. Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Reactive oxygen species and cancer paradox: To promote or to suppress? Free Radic Biol Med. 2017 Mar;104:144-164. https://doi.org/10.1016/j.freeradbiomed.2017.01.004

13. Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. Cancer Lett. 2017 Feb 28;387:95-105. https://doi.org/10.1016/jxanlet.2016.03.04.

14. Helfinger V, Schroder K. Redox control in cancer development and progression. Mol Aspects Med. 2018 Oct;63:88-98. https://doi.org/10.1016/j.mam.2018.02.003

15. Goroshinskaya IA, Surikova EI, Shalashnaya EV, Nerodo GA, Maksimova NA, Men'shenina AP, et al. State of free radical processes in ovarian cancer with different prevalence and course of the disease. University News North Caucasus region. Natural Sciences. 2017;(4-2(196-2)):10-19. (In Russ.). https://doi.org/10.23683/0321-3005-2017-4-2-10-19

16. Rozenko LYA, Sidorenko YuS, Franzyants EM. Does the volume of the tumor affect the state of the antioxidant defense of the body? Questions of oncology. 1999;45(5):538-541. (In Russ.).

17. Menshchikova EB, Zenkov NK, Lankin VZ, Bondar IA, Trufakin VA. Oxidative stress. Pathological conditions and diseases. Novosibirsk: Siberian University Publishing House. 2017, 284 p. (In Russ.).

18. Corso CR, Acco A. Glutathione system in animal model of solid tumors: From regulation to therapeutic target. Crit Rev Oncol He-matol. 2018 Aug;128:43-57. https://doi.org/10.1016/jxritrevonc.2018.05.014

19. Sirota TV. Effect of the sulfur-containing compounds on the quinoid process of adrenaline autoxidation; potential neuroprotectors. Biomeditsinskaya Khimiya. 2019;65(4):316-323. https://doi.org/10.18097/PBMC20196504316

20. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 2016 Jan 1;76(1):7-9. https://doi.org/10.1158/0008-5472.CAN-15-3143

21. Dong S-C, Sha H-H, Xu X-Y, Hu T-M, Lou R, Li H, et al. Glutathione S-transferase n: a potential role in antitumor therapy. Drug Des Devel Ther. 2018 Oct 23;12:3535-3547. https://doi.org/10.2147/DDDT.S169833

22. Goroshinskaya IA, Medvedeva DE, Surikova EI, Nemashkalova LA., Kachesova PS., Maslov AA, Kit OI. State of oxidative metabolism in the blood of gastric cancer patients with various tumor histotypes. Modern problems of science and education. 2019;(1):3. (In Russ.).

23. Harutyunyan AV, Dubinina EE, Zybina NN. Methods of evaluation of free radical oxidation and the antioxidant system of the body. Methodological recommendations. St. Petersburg: LLC "Foliant Publishing House”. 2000, 104 p. (In Russ.).

24. Rusetskaya NY, Fedotov IV, Koftina VA, Borodulin VB. Selenium compounds in redox regulation of inflammation and apoptosis. Biomeditsinskaya Khimiya. 2019;65(3):165-179. (In Russ.). https://doi.org/10.18097/PBMC20196503165

25. Hatem E, El Banna N, Huang M-E. Multifaceted roles of glutathione and glutathione-based systems in carcinogenesis and anticancer drug resistance. Antioxid Redox Signal. 2017 Nov 20;27(15):1217-1234. https://doi.org/10.1089/ars.2017.7134

26. Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018 Jul 2;217(7):2291-2298. https://doi.org/10.1083/jcb.201804161

27. Goroshinskaya IA, Surikova EI, Frantsiyants EM, Neskubina IV, Nemashkalova LA, Medvedeva DE, et al. Redox forms of glutathione in malignant lesions of the stomach with varying aggressiveness degrees. Bulletin of Siberian Medicine. 2020;19(4):53-60. https://doi.org/10.20538/1682-0363-2020-4-53-60

28. Bel'skaya LV, Kosenok VK, Massard Zh. System of lipid peroxidation and antioxidant protection of saliva in lung cancer. Russian Clinical Laboratory Diagnostics. 2018;63(9):530-537. (In Russ.). https://doi.org/10.18821.0869-2084-2018-63-9-530-537

29. Nunes SC, Serpa J. Glutathione in ovarian cancer: A double-edged sword. Int J Mol Sci. 2018 Jun 26;19(7):1882. https://doi.org/10.3390/ijms19071882

30. Goroshinskaya I, Popova N, Menshenina A, Nemashkalova L, Shikhlyarova A, Frantsiyants E, et al. Free radical processes in the blood of patients with cervical cancer receiving various postoperative treatment modalities. International Journal of Gynecologic Cancer. 2019;29(Suppl 4):A218. https://doi.org/10.1136/ijgc-2019-ESGO.362